Potential Risks Common: Nausea (peaks week 4-8), diarrhea, constipation
When attending an appointment, it may be helpful to: Bring a list of your current medications , including any supplements or over-the-counter products Discuss your weight history and previous treatment attempts , including any prior use of GLP-1 agonists Ask specifically about clinical trial eligibility , as some NHS trusts and academic centres are actively recruiting for obesity-related studies Raise any concerns about online sources offering unlicensed peptides, so your clinician can provide appropriate safety guidance Your GP can refer you to NHS Tier 3 specialist weight management services if you meet the relevant criteria
While our nested casecontrol design, PSM analyses, dynamic PDC-based exposure assessment, and subgroup analyses help mitigate these concerns, they cannot fully eliminate them
Enantiomers were separated and according to computational modeling the inhibitory capacity of the compounds were attributed to the S -configuration of the spiro-oxindole dihydroquinazolinones